Evidence map›Paper›PMID 39981972›Full record

ReviewEpigenomics2025

A narrative review of epigenetic marker in H3K27ac and its emerging potential as a therapeutic target in cancer.

Meizi Zhu, Xuejin Lu, Danhong Wang, Jinhu Ma, Yi Wang, Rui Wang, Hongye Wang, Wenhui Cheng, Yaling Zhu

Abstract readReview
In one paragraph

Review in Epigenomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Epigenomic landscape of nasopharyngeal carcinoma.Medical oncology (Northwood, London, England) · 2025
    Review
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Meizi ZhuDepartment of Pathophysiology, College of Basic Medical Science, Anhui Medical University, Hefei, China.
Xuejin LuDepartment of Pathophysiology, College of Basic Medical Science, Anhui Medical University, Hefei, China.
Danhong WangDepartment of Pathophysiology, College of Basic Medical Science, Anhui Medical University, Hefei, China.
Jinhu MaDepartment of Pathophysiology, College of Basic Medical Science, Anhui Medical University, Hefei, China.
Yi WangDepartment of Pathophysiology, College of Basic Medical Science, Anhui Medical University, Hefei, China.
Rui WangDepartment of Pathophysiology, College of Basic Medical Science, Anhui Medical University, Hefei, China.
Hongye WangDepartment of Pathophysiology, College of Basic Medical Science, Anhui Medical University, Hefei, China.
Wenhui ChengLaboratory Animal Research Center, College of Basic Medical Science, Anhui Medical University, Hefei, China.
Yaling ZhuDepartment of Pathophysiology, College of Basic Medical Science, Anhui Medical University, Hefei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Histone acetylation, particularly H3 K27 acetylation (H3K27ac), is a critical post-translational modification that regulates chromatin structure and gene expression, which plays a significant role in various cancers, including breast, colon, lung, hepatocellular, and prostate cancer. However, the mechanisms of H3K27ac in tumorigenesis are not yet comprehensive, especially its epigenetic mechanisms. This review endeavors to discuss findings on the involvement of H3K27ac in carcinogenesis within the past 5 years through a literature search using academic databases such as Web of Science. Firstly, we provide an overview of the diverse landscape of histone modifications, emphasizing the distinctive characteristics and critical significance of H3K27ac. Secondly, we summarize and compare advanced high-throughput sequencing technologies that have been utilized in the construction of the H3K27ac epigenetic map. Thirdly, we elucidate the role of H3K27ac in mediating gene transcription. Fourthly, we venture into the potential molecular mechanism of H3K27ac in cancer development. Finally, we engage in discussing future therapeutic approaches in oncology, with a spotlight on strategies that harness the potential of H3K27 modifications. In conclusion, this review comprehensively summarizes the characteristics of H3K27ac and underscores its pivotal role in cancer, providing valuable insights into its potential as a therapeutic target for cancer intervention.

Indexed as

Biomarkers, TumorEpigenesis, GeneticHistonesNeoplasmsAcetylationAnimalsGene Expression Regulation, NeoplasticHumansProtein Processing, Post-TranslationalBiomarkers, TumorHistonescancerepigenetic markerH3K27acmechanismstherapeutic targets

Identifiers

PMID39981972
PMCPMC11853624

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.